A Bcr-Abl inhibitor (IC50 1.2 nM) selective for Bcr-Abl over VEGFR2 c-Src EGFR and HER2 at 1 UM but does inhibit PDGFRB and c-Kit (IC50s 307.6 and 665.5 nM respectively) inhibits the proliferation of K562 cells expressing wild-type Bcr-Abl (IC50 5.1 nM) and 32D cells expressing the Bcr-Abl mutations Bcr-AblQ252H Bcr-AblY253F Bcr-AblE255K Bcr-AblM351T and Bcr-AblH396P (IC50s 76.3 40.4 123.2 20.2 and 34.6 nM respectively) which are resistant to imatinib induces tumor regression and increases survival time in a K562 mouse xenograft model at 75 mg/kg per day increases the viability of SARS-CoV-2-infected Vero E6 cells (EC50 1.6 UM)